Raymond James Financial Services Advisors
PVLA icon

Raymond James Financial Services Advisors’s Palvella Therapeutics PVLA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-325
Closed -$59K – 2917
2020
Q1 		$59K Buy
+325
New +$81.9K ﹤0.01% 2300

Other funds holding PVLA

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial Services Advisors's PVLA Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of Palvella Therapeutics (PVLA) in Q2 2020, closing a stake of 325 shares — an estimated $59K sold.

Raymond James Financial Services Advisors first reported a position in PVLA in Q1 2020 and held it in 1 quarter. The position peaked at $59K in Q1 2020. 96 funds tracked by Wall St. Rank hold PVLA as of Q2 2020.

  • Raymond James Financial Services Advisors reported no remaining Palvella Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 325 Palvella Therapeutics shares in Q2 2020, an estimated $59K.
  • Raymond James Financial Services Advisors first reported a position in Palvella Therapeutics in Q1 2020 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Palvella Therapeutics position peaked at $59K in Q1 2020.
  • 96 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.